Genomic screens for genes upregulated by demethylation in colorectal cancer: Possible usefulness for clinical application

International Journal of Oncology

Volumn 27, Issue 2, 2005, Pages 417-426

  Ogawa, Kazuhiko ^a,b   Utsunomiya, Tohru ^a   Mimori, Koshi ^a   Yamashita, Keishl ^a,c   Okamoto, Masahlro ^a   Tanaka, Fumiaki ^a   Inoue, Hiroshi ^a   Ikeda, Yoichi ^d   Saku, Motonori ^d   Murayama, Sadayuki ^b   Mori, Masaki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Colorectal neoplasms; DNA methyltransferase inhibitors; Methylalion; Microarray; Prognostic factors

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; APOLIPOPROTEIN; APOLIPOPROTEIN D; AZACITIDINE; MESSENGER RNA;

AGED; ARTICLE; CELL STRAIN HT29; COLORECTAL TUMOR; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; GENOME; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; SURVIVAL; TUMOR CELL LINE; UPREGULATION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; APOLIPOPROTEINS; APOLIPOPROTEINS D; AZACITIDINE; BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 33644688398     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.2.417     Document Type: Article

References (54)

1. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
2. Feinberg AP: Cancer epigenetics lakes center stage. Proc Natl Acad Sci USA 98: 392-394.2001.
3. Baker SJ. Markowitz. S. Fearon ER. Willson JK and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915. 1990.
4. Nishisho I. Nakamura Y. Miyoshi Y. et al: Mutations of chromo-some 5q21 genes in FAP and colorectal cancer patients. Science 253:665-669. 1991.
5. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hvpermethylation. N Engl J Med 349: 2042-2054.2003.
6. Li H. Myeroff L. Smiraglia D. et al: SLC5A8. a sodium transporter, is a tumor suppressor gene silenced by mcthylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA 100: 8412-8417. 2003.
7. Wiencke JK. Zheng S. Lafuente A. et al: Aberrant mcthylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev 8:501-506. 1999.
8. ,INK4a mcthylation and p53 mutational status. Cancer Res 60: 129-133. 2000.
9. Nagasaka T. Sharp GB. Notohara K. et al: Hypermethylation of 06-methylguaninc-DNA methyltransferase promoter may predict non-recurrence after chemotherapy in colorectal cancer cases. Clin Cancer Res 9: 5306-5312. 2003.
10. Paz. MF. Wei S. Cigudosa JC. et al: Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyJtransferasex. Hum Mol Genet 12: 2209-2219. 2003.
11. Karpf AR and Jones DA: Reactivating the expression of mcthylation silenced genes in human cancer. Oncogene 21: 5496-5503. 2002.
12. Karpf AR. Peterson PW. Rawlins JT. et al: Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator ol' transcription I. 2. and 3 genes in colon tumor cells. Proc Natl Acad Sci USA 96: 14007-14012. 1999.
13. Yamashita K. Upadhyay S. Osada M. et al: Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2: 485-495. 2002.
14. Suzuki H. Gabrielson E. Chen W. et al: A genomic screen for genes upregulated by demehtylation and histone dcacetylasc inhibition in human colorectal cancer. Nat Genet 31: 141-149. 2002.
15. Shi H. Wei SH. Leu YW. et al: Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression. DNA methvlation. and histone acetylation. Cancer Res 63: 2164-2171.2003.
16. Liang G. Gonzales FA. Jones PA. Orntol't TF and Thykjaer T: Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-Aza-2'- deoxycytidine. Cancer Res 62: 961-966. 2002.
17. Yamada Y. Watanabe M. Yamanaka M. et al: Aberrant methylation ol the vascular endothelial growth factor receptor-1 gene in prostate cancer. Cancer Set 94: 536-539. 2003.
18. Sato N. Fukushima N. Maura A. et al: Discovery of novel targets for aberrant mcthylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63: 3735-3742. 2(X)3.
19. Fukai K. Yokosuka O. Chiba T. et al.: Hepatocyte growth factor activator inhibitor 2/plaeentai bikunin (HAI-2/PB) gene is frequently hvpermethylaied in human hepatocellular carcinoma. Cancer Res 63: 8674-8679. 2004.
20. Pompeia C. Hodge D. Plass C. et al: Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res 64: 3465-3473. 2004.
21. Mori M. Barnard GF. Staniunas RJ. Jessup JM. Steele GD Jr and Chen LB: Prothymosin-alpha mRNA expression cor-relates with that of c-mye in human colon cancer. Oncogene 8: 2821-2826. 1993.
22. Yamashita K. Mori M. Kataoka A. Inouc II and Sugimachi K: The clinical significance of MMP-I expression in oesophageal carcinoma. Br J Cancer 84: 276-282. 2001.
23. Inouc II. Mori M. Honda M. et al: The expression of tumor-rejection antigen 'MAGE' genes in human gastric carcinoma. Gastroenterology 109: 1522-1525. 1995.
24. Mori M. Inouc II. Mimnri K. et al: Expression of MAGE genes in human colorectal carcinoma. Ann Surg 224: 183-188, 1996.
25. Mashino K. Sadanaga N. Tanaka F. et al: Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 85: 713-720.2001.
26. Yang YII. Dudoit S. Luu P. et al: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30: E15.2002.
27. Masuda TA. Inouc II. Nishida K. et al: Cyelin-dependent kinase I gene expression is associated with poor prognosis in gastric carcinoma. Clin Cancer Res 9: 5693-5698. 2003.
28. Ogawa K. Utsunomiya T. Mimori K. et al: Clinical significance of elongation factor-1 delta mRNA expression in oesophageal carcinoma. Br J Cancer 91: 282-286. 2004.
29. Yamashita K. Mimori K. Inoue II. Mori M and Sidransky D: Atumor-suppressive role for trypsin in human cancer progression. Cancer Res 63: 6575-6578. 2003.
30. Kaplan EL and Meier P: Non-parametrie estimation from incomplete observations. J Am Slat Assoe 53: 457-481. 1958.
31. Mantel N: Evaluation of survival data and two new rank order statisties arising in its consideration. Cancer Chemother Rep 50: 163-170. 1966.
32. Gardiner-Garden M and Frommer M: CpG islands in vertebrate genomes. J Mol Biol 196: 261-282. 1987.
33. Coral S. Sigaloni L. Altomonle M. et al: 5-Aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 8: 2690-2695. 2002.
34. Bert T. Lubomierski N. Gangsauge S. et al: Expression spectrum and methylation-dependent regulation of melanoma antigen-encoding gene family members in pancreatic cancer cells. Pancreatology 2: 146-154. 2002.
35. Sigalotti L. Coral S. Nardi G. et al: Promoter mcthylation controls the expression of MAGE2, 3 and 4 genes in human cutaneus melanoma. J Immunother 25: 16-26, 2002.
36. Sigalotti L. Coral S. Altomonlc M. et al: Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer 86: 979-982. 2002.
37. De Smet C. Lurquin C. Lethe B. Martelange V and Boon T: DNA methylation is the primary silencing mechanism for a set of germ line-and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19: 7327-7335. 1999.
38. De Smet C. De Backer O. Faraoni I. Lurquin C. Brasseur F and Boon T: The activation of human gene MAGE-I in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 93: 7149-7153. 1996.
39. Karpf AR. Lasek AW, Ririe TO. Hanks AN. Grossman D and Jones DA: Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-Aza-2'-deoxycylidine. Mol Pharmacol 65: 18-27. 2004.
40. Arias AM. Brown AM and Brennan K: Wnt signaling: pathway or network? Curr Opin Genet Dev 9: 447-454. 1999.
41. Wissmann C. Wild PJ. Kaiser S. et al. WIFI, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201: 204-212. 2003.
42. Mazienes J. He B. You L. el at: Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64:4717-4720. 2004.
43. Suzuki H. Watkins DN. Jair KW. et al: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36:417-422. 2004.
44. Caldwell GM. Jones C. Gensberg K. et al: The Wnt antagonist sFRPI in colorectal tumorigenesis. Cancer Res 64: 883-888. 2004.
45. McConathy WJ and Alaupovic P: Isolation and partial character-ization of apolipoprotein D: a new protein moiety of the human plasma lipoprotein system. FEBS Lett 37: 178-182. 1973.
46. Drayna D. Fielding C. McLean J. et al: Cloning and expression of human apolipoprotein D cDNA. J Biol Chem 261: 16535-16539. 1986.
47. Do Carmo S. Seguin D. Milne R and Rassart E: Modulation of apolipoprotein D and apolipoprotein E mRNA expression by growth arrest and identification of key elements in the promoter. J Biol Chem 277: 5514-5523. 2002.
48. Diez-ltza I. Vizoso F. Merino AM. et al: Expression and prognostic significance of apolipoprotein D in breast cancer. Am J Pathol 144: 310-320. 1994.
49. Vazquez J. Gonzalez L. Merino A and Vizoso F: Expression and clinical significance of apolipoprotein D in epithelial ovarian carcinomas. Gynecol Oncol 76: 340-347. 2000.
50. Brock MV. Gou M. Akiyama Y. et al: Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9: 2912-2919. 2003.
51. Muller HM. Widchwendter A. Fiegl H, et al: DNA methylation of breast cancer patients: an independent prognostic marker. Cancer Res 63: 7641-7645. 2003.
52. Widschwendter A. Muller HM. Fiegl H. ei at: DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 10: 565-571. 2004.
53. Cameron EE. Bachman KE. Myohanaen S. Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107. 1999.
54. Gius D. Cui II. Bradbury CM. et al: Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6: 361-371.2004.